Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2020/878 - Malta

SAFETY DATA SHEET



SUPREMO KLARLACK 3990-02 - All variants

SECTION 1: Identification of the substance/mixture and of the company/ undertaking

1.1 Product identifier

Product name

: SUPREMO KLARLACK 3990-02 - All variants

1.2 Relevant identified uses of the substance or mixture and uses advised againstProduct use: Paint.

1.3 Details of the supplier of the safety data sheet

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

e-mail address of person : Prod-safe@teknos.com

responsible for this SDS

National contact

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

1.4 Emergency telephone number

National advisory body/Poison Centre

 Telephone number
 : Malta Competition and Consumer Affairs Authority (MCCAA): +356 2395 2000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Product definition : Mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Flam. Liq. 2, H225 Eye Irrit. 2, H319 Skin Sens. 1, H317 STOT SE 3, H336 Aquatic Chronic 3, H412

The product is classified as hazardous according to Regulation (EC) 1272/2008 as amended.

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

2.2 Label elements

Hazard pictograms



Signal word	Danger	
Hazard statements	H225 - Highly flammable liquid and vapour. H317 - May cause an allergic skin reaction. H319 - Causes serious eye irritation. H336 - May cause drowsiness or dizziness. H412 - Harmful to aquatic life with long lasting effects.	
Precautionary statements		
Prevention	P280 - Wear protective gloves. Wear eye or face protection. P210 - Keep away from heat, hot surfaces, sparks, open flames and other ignit sources. No smoking. P273 - Avoid release to the environment.	tion

Date of issue/Date of revision	: 20/12/2023	Date of previous issue	: No previous validation	Version	:1	1/19
SUPREMO KLARLACK 3990-02 -	All variants			Label No	52114	ļ

SECTION 2: Hazards identification

SECTION 2. Hazarus		
Response	1	P304 + P312 - IF INHALED: Call a POISON CENTER or doctor if you feel unwell.
Storage	:	P403 + P233 - Store in a well-ventilated place. Keep container tightly closed.
Disposal	:	P501 - Dispose of contents and container in accordance with all local, regional, national and international regulations.
Hazardous ingredients	:	Contains: n-Butyl acetate; Ethyl acetate; EO bis(benztriazolyl)phenylpropionat and Methyl methacrylate
Supplemental label elements	:	
Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles	:	
2.3 Other hazards		
Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII	:	This mixture does not contain any substances that are assessed to be a PBT or a vPvB.
Other hazards which do	:	None known.

not result in classification

SECTION 3: Composition/information on ingredients

Product/ingredient name	Identifiers	%	Classification	Specific Conc. Limits, M-factors and ATEs	Туре
n-Butyl acetate	REACH #: 01-2119485493-29 EC: 204-658-1 CAS: 123-86-4 Index: 607-025-00-1	≥25 - ≤50	Flam. Liq. 3, H226 STOT SE 3, H336 EUH066	-	[1] [2]
Ethyl acetate	REACH #: 01-2119475103-46 EC: 205-500-4 CAS: 141-78-6 Index: 607-022-00-5	≥10 - ≤25	Flam. Liq. 2, H225 Eye Irrit. 2, H319 STOT SE 3, H336 EUH066	-	[1] [2]
Butanone	REACH #: 01-2119457290-43 EC: 201-159-0 CAS: 78-93-3 Index: 606-002-00-3	≥10 - ≤25	Flam. Liq. 2, H225 Eye Irrit. 2, H319 STOT SE 3, H336 EUH066	-	[1] [2]
Naphtha (petroleum), hydrotreated light	EC: 265-151-9 CAS: 64742-49-0 Index: 649-328-00-1	≥10 - <25	Flam. Liq. 2, H225 Asp. Tox. 1, H304 Aquatic Chronic 2, H411	-	[1]
2-Methoxy-1-methylethyl acetate	REACH #: 01-2119475791-29 EC: 203-603-9 CAS: 108-65-6 Index: 607-195-00-7	≤5	Flam. Liq. 3, H226	-	[2]
Xylene	REACH #: 01-2119488216-32 EC: 215-535-7 CAS: 1330-20-7	≤5	Flam. Liq. 3, H226 Acute Tox. 4, H312 Acute Tox. 4, H332 Skin Irrit. 2, H315	ATE [Dermal] = 1100 mg/kg ATE [Inhalation (vapours)] = 11 mg/	[1] [2]

SUPREMO KLARLACK 3990-02 - All variants

	Index: 601-022-00-9		Eye Irrit. 2, H319 STOT SE 3, H335 STOT RE 2, H373 (oral, inhalation) Asp. Tox. 1, H304	1	
EO bis(benztriazolyl) phenylpropionat	REACH #: 01-0000015075-76 EC: 400-830-7 CAS: 104810-48-2 Index: 607-176-00-3	<1	Skin Sens. 1A, H317 Aquatic Chronic 2, H411	-	[1]
Methyl methacrylate	REACH #: 01-2119452498-28 EC: 201-297-1 CAS: 80-62-6 Index: 607-035-00-6	≤0.3	Flam. Liq. 2, H225 Skin Irrit. 2, H315 Skin Sens. 1, H317 STOT SE 3, H335	-	[1] [2]
			See Section 16 for the full text of the H statements declared above.		

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

Type

[1] Substance classified with a health or environmental hazard

[2] Substance with a workplace exposure limit

Occupational exposure limits, if available, are listed in Section 8.

SECTION 4: First aid measures

4.1 Description of first aid measures

Eye contact	: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention.
Inhalation	: Remove victim to fresh air and keep at rest in a position comfortable for breathing. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention. If necessary, call a poison center or physician. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.
Skin contact	: Wash with plenty of soap and water. Remove contaminated clothing and shoes. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. Continue to rinse for at least 10 minutes. Get medical attention. In the event of any complaints or symptoms, avoid further exposure. Wash clothing before reuse. Clean shoes thoroughly before reuse.
Ingestion	: Wash out mouth with water. Remove dentures if any. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention. If necessary, call a poison center or physician. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.
Protection of first-aiders	: No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves.
Date of issue/Date of revision	: 20/12/2023 Date of previous issue : No previous validation Version : 1 3/19

4.2 Most important symptoms and effects, both acute and delayed

Over-exposure signs/symptoms

Eye contact	: Adverse symptoms may include the following: pain or irritation watering redness
Inhalation	: Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness
Skin contact	: Adverse symptoms may include the following: irritation redness
Ingestion	: No specific data.
4.3 Indication of any im	mediate medical attention and special treatment needed

Notes to physician	: Treat symptomatically. Contact poison treatment specialist immediately if large
	quantities have been ingested or inhaled.
Specific treatments	: No specific treatment.

SECTION 5: Firefighting measures

5.1 Extinguishing media	
Suitable extinguishing media	: Use dry chemical, CO ₂ , water spray (fog) or foam.
Unsuitable extinguishing media	: Do not use water jet.

5.2 Special hazards arising from the substance or mixture

Hazards from the substance or mixture	:	Highly flammable liquid and vapour. Runoff to sewer may create fire or explosion hazard. In a fire or if heated, a pressure increase will occur and the container may burst, with the risk of a subsequent explosion. This material is harmful to aquatic life with long lasting effects. Fire water contaminated with this material must be contained and prevented from being discharged to any waterway, sewer or drain.
Hazardous combustion products	:	Decomposition products may include the following materials: carbon dioxide carbon monoxide metal oxide/oxides
5.3 Advice for firefighters		
Special protective actions for fire-fighters	:	Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training. Move containers from fire area if this can be done without risk. Use water spray to keep fire-exposed containers cool.
Special protective equipment for fire-fighters	:	Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

SECTION 6: Accidental release measures

6.1 Personal precautions, pro	ote	ctive equipment and emergency procedures
For non-emergency personnel	:	No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Shut off all ignition sources. No flares, smoking or flames in hazard area. Avoid breathing vapour or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.
For emergency responders	-	If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".
6.2 Environmental precautions	:	Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air). Water polluting material. May be harmful to the environment if released in large quantities.
6.3 Methods and material for	со	ntainment and cleaning up
Small spill	:	Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
Large spill	:	Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Approach the release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations. Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilt product.
6.4 Reference to other sections	:	See Section 1 for emergency contact information. See Section 8 for information on appropriate personal protective equipment. See Section 13 for additional waste treatment information.

SECTION 7: Handling and storage

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

7.1 Precautions for safe handling

Protective measures	Put on appropriate personal protective equipment (see Section 8). Persons with a history of skin sensitization problems should not be employed in any process in which this product is used. Do not get in eyes or on skin or clothing. Do not ingest. Avoid breathing vapour or mist. Avoid release to the environment. Use only with adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Do not enter storage areas and confined spaces unless adequately ventilated. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Store and use away from heat, sparks, open flame or any other ignition source. Use explosion-proof electrical (ventilating, lighting and material handling) equipment. Use only non-sparking tools. Take precautionary measures against electrostatic discharges. Empty containers retain product residue and can be hazardous. Do not reuse container.
Advice on general occupational hygiene	Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

7.2 Conditions for safe storage, including any incompatibilities

SECTION 7: Handling and storage

Store in accordance with local regulations. Store in a segregated and approved area. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Eliminate all ignition sources. Separate from oxidising materials. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination.

Seveso Directive - Reporting thresholds

Danger criteria

	Notification and MAPP threshold	Safety report threshold
P5c	5000 tonne	50000 tonne

7.3 Specific end use(s)

Industrial sector specific : Not available. solutions

SECTION 8: Exposure controls/personal protection

: Not available.

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

8.1 Control parameters

Occupational exposure limits

Product/ingredient name	Exposure limit values
n-Butyl acetate	EU OEL (Europe, 1/2022). Notes: list of indicative
	occupational exposure limit values
	STEL: 150 ppm 15 minutes.
	STEL: 723 mg/m ³ 15 minutes.
	TWA: 241 mg/m ³ 8 hours.
	TWA: 50 ppm 8 hours.
Ethyl acetate	EU OEL (Europe, 1/2022). Notes: list of indicative
	occupational exposure limit values
	STEL: 400 ppm 15 minutes.
	STEL: 1468 mg/m ³ 15 minutes.
	TWA: 200 ppm 8 hours.
	TWA: 734 mg/m ³ 8 hours.
Butanone	EU OEL (Europe, 1/2022). Notes: list of indicative
	occupational exposure limit values
	TWA: 200 ppm 8 hours.
	TWA: 600 mg/m³ 8 hours.
	STEL: 300 ppm 15 minutes.
	STEL: 900 mg/m ³ 15 minutes.
2-Methoxy-1-methylethyl acetate	EU OEL (Europe, 1/2022). Absorbed through skin. Notes: list
	of indicative occupational exposure limit values
	TWA: 50 ppm 8 hours.
	TWA: 275 mg/m ³ 8 hours.
	STEL: 100 ppm 15 minutes.
	STEL: 550 mg/m ³ 15 minutes.
Xylene	EU OEL (Europe, 1/2022). [xylene, mixed isomers pure]
	Absorbed through skin. Notes: list of indicative occupational
	exposure limit values
	TWA: 50 ppm 8 hours.
	TWA: 221 mg/m ³ 8 hours.
	STEL: 100 ppm 15 minutes.
	STEL: 442 mg/m ³ 15 minutes.
Methyl methacrylate	EU OEL (Europe, 1/2022). Notes: list of indicative
	occupational exposure limit values
	TWA: 50 ppm 8 hours.
	STEL: 100 ppm 15 minutes.

Date of issue/Date of revision: 20/12/2023SUPREMO KLARLACK 3990-02 - All variants

D23 Date of previous issue

SECTION 8: Exposure controls/personal protection

Biological exposure indices

Product/ingredient name		Exposure indices
No exposure indices known.		
Recommended monitoring procedures	European Stance assessment of e values and mea atmospheres - (of exposure to c (Workplace atm for the measure	Id be made to monitoring standards, such as the following: lard EN 689 (Workplace atmospheres - Guidance for the exposure by inhalation to chemical agents for comparison with limit surement strategy) European Standard EN 14042 (Workplace Guide for the application and use of procedures for the assessment chemical and biological agents) European Standard EN 482 ospheres - General requirements for the performance of procedures ment of chemical agents) Reference to national guidance nethods for the determination of hazardous substances will also be

DNELs/DMELs

Product/ingredient name	Туре	Exposure	Value	Population	Effects
n-Butyl acetate	DNEL	Short term Oral	2 mg/kg	General	Systemic
-			bw/day	population	-
	DNEL	Long term Oral	2 mg/kg	General	Systemic
		J	bw/day	population	,
	DNEL	Short term Dermal	6 mg/kg	General	Systemic
			bw/day	population	-)
	DNEL	Short term Dermal	11 mg/kg	Workers	Systemic
			bw/day		
	DNEL	Long term	35.7 mg/m ³		Local
		Inhalation		population	
	DNEL	Short term	300 mg/m ³	General	Local
		Inhalation	-	population	
	DNEL	Short term	300 mg/m³	General	Systemic
		Inhalation		population	,
	DNEL	Long term	300 mg/m ³	Workers	Local
		Inhalation	SSS mg/m		
	DNEL	Short term	600 mg/m³	Workers	Local
	DNEL		ooo mg/m	WUNCIS	LUCAI
		Inhalation	600 m / 3	\A/aukaus	Curata maila
	DNEL	Short term	600 mg/m ³	Workers	Systemic
	D	Inhalation			
	DNEL	Long term Dermal	3.4 mg/kg	General	Systemic
			bw/day	population	
	DNEL	Long term Dermal	7 mg/kg	Workers	Systemic
			bw/day		
	DNEL	Long term	12 mg/m ³	General	Systemic
		Inhalation	J.	population	
	DNEL	Long term	48 mg/m³	Workers	Systemic
		Inhalation	. eg/		5,000,000
Ethyl acetate	DNEL	Long term Oral	4.5 mg/kg	General	Systemic
Lity averale		Long term Oral	bw/day		Systemic
		Long torm Dormal		population	Sustamia
	DNEL	Long term Dermal	37 mg/kg	General	Systemic
	D		bw/day	population	
	DNEL	Long term Dermal	63 mg/kg bw/day	Workers	Systemic
		Long torm		General	Local
	DNEL	Long term	367 mg/m ³		LUCAI
		Inhalation	007 - 4-3	population	O un transition
	DNEL	Long term	367 mg/m³	General	Systemic
		Inhalation		population	
	DNEL	Short term	734 mg/m³	General	Local
		Inhalation		population	
	DNEL	Short term	734 mg/m ³	General	Systemic
		Inhalation	Ŭ Ŭ	population	
	DNEL	Long term	734 mg/m³	Workers	Local
		Inhalation			
	DNEL	Long term	734 mg/m³	Workers	Systemic
	DNEL	Inhalation	7 34 mg/m	VV UINCIS	Systemic
	DNEL	Short term	1468 mg/	\A/aukaus	
		I Short term	14b8 md/	Workers	Local

Date of issue/Date of revision: 20/12/2023SUPREMO KLARLACK 3990-02 - All variants

: 20/12/2023 Date of previous issue

: No previous validation

Version :1 7/19 Label No :52114

DNELShort term inhalation1468 mg/ m²WorkersSystemicJutanoneDNELLong term Oral31 mg/kg bw/dayGeneral oppulationSystemic populationJutanoneDNELLong term Oral116 mg/m²General oppulationSystemic populationJutanoneDNELLong term Dermal inhalation1161 mg/ DNELSystemic populationSystemic populationJutanoneDNELLong term Dermal inhalation1161 mg/ inhalationWorkersSystemic populationJutanoneDNELLong term Dermal inhalation1.9 mg/m² inhalationSystemic populationSystemic populationJutanoneDNELLong term Dermal inhalation1.9 mg/m² inhalationSystemic populationSystemic populationDNELLong term Dermal inhalation1.9 mg/m² inhalationGeneral populationSystemic populationDNELLong term Dermal inhalation1.9 mg/m² inhalationSystemic populationSystemic populationDNELLong term Dermal inhalation1.9 mg/m² inhalationSystemic populationSystemic inhalationDNELLong term Dermal inhalation1.9 mg/m² inhalationSystemic inhalationSystemic inhalationDNELLong term Dermal inhalation1.9 mg/m² inhalationSystemic inhalationSystemic inhalationDNELLong term Dermal inhalation1.9 mg/m² inhalationSystemic inhalationSystemic inhalation<			Inhalation	m³			
JutanoneDNELLong term OralJing/kg bw(ay bw(ay)General opulationSystemic opulationNELLong term Dermal Inhalation106 mg/mGeneral opulationSystemicNELLong term Dermal Inhalation116 mg/mGeneral opulationSystemicVaphtha (petroleum), hydrotreated ightDNELLong term Dermal Inhalation116 mg/mGeneral opulationSystemicVaphtha (petroleum), hydrotreated ightDNELLong term Dermal Inhalation116 mg/mGeneral opulationSystemicNELLong term Dermal Inhalation19 mg/mGeneral opulationSystemicDNELLong term Oral Inhalation19 mg/mGeneral opulationSystemicDNELLong term Oral Inhalation19 mg/mGeneral opulationSystemicDNELLong term Oral Inhalation19 mg/mGeneral opulationSystemicDNELShort term Inhalation178.57 mg/mGeneral opulationSystemicDNELShort term Inhalation178.57 mg/mGeneral opulationSystemicDNELShort term Inhalation178.67 mg/mGeneral opulationSystemicDNELLong term Inhalation178.67 mg/mGeneral opulationSystemicDNELLong term Inhalation178.67 mg/mGeneral opulationSystemicDNELLong term Inhalation375 mg/mGeneral opulationSystemicDNELLong term Inhalation <th></th> <th>DNEL</th> <th></th> <th></th> <th>Workers</th> <th>Systemic</th> <th></th>		DNEL			Workers	Systemic	
Name Downer Description population population Vaphtha (petroleum), hydrotreated (ght DNEL Long term Dermal 106 mg/m² General Systemic Vaphtha (petroleum), hydrotreated DNEL Long term Dermal 116 mg/m² General Systemic Japhtha (petroleum), hydrotreated DNEL Long term Dermal 116 mg/m² Workers Systemic Japhtha (petroleum), hydrotreated DNEL Long term Dermal 149 mg/kg General Systemic DNEL Long term Dermal 149 mg/kg General Systemic DNEL Long term Dermal 149 mg/kg General Local DNEL Long term Dermal 149 mg/kg General Local DNEL Long term Dermal 178.57 mg/ General Local DNEL Long term Dermal 1066.67 mg/kg General Local DNEL Long term Dermal 1076.75 mg/m Workers Systemic DNEL Long term Dermal 1076.67 mg/m General Systemic							
NumberNumberLong term permai inhalation DNELLong term permai population 	Butanone	DNEL	Long term Oral			Systemic	
Naphtha (petroleum), hydrotreated (ghtDNEL Long term Dermal halation DNEL Long term Dermal halation mandation maphation maphation maphation population population general population							
NEL Apphtha (petroleum), hydrotreated ightDNEL Long term Dermal inhalation DNEL Long term Dermal Long term Dermal inhalation DNEL Long term Oral412 mg/kg bw/day Ceneral DMC Ceneral DMC SystemicSystemic Systemic SystemicVaphtha (petroleum), hydrotreated ightDNEL Long term Oral Inhalation DNEL Long term Oral161 mg/ NorkersWorkers Systemic Systemic DMC DNEL Long term Oral Inhalation DNEL Long term OralWorkers Systemic Systemic DMC DMC Long term Oral 149 mg/kg DMC DMCL Long term Oral DMCL Long term Oral 149 mg/kg DMCL Long term Oral DMCL Long term Oral DMCL Long term Oral Inhalation m* DMCL DMCL Long term DMCL Long term Dermal DMCL Long term Dermal DMCL DMCL Long term Dermal DMCL DMCL Long term Dermal DMCL DMCL Long term Dermal DMCL DMCL Long term Dermal DMCL DMCL DMCL DMCL Long term Dermal DMCL DMCL DMCL Long term Dermal DMCL DMCL DMCL DMCL DMCL D		DNEL		106 mg/m ³		Systemic	
Naphtha (petroleum), hydrotreated ightDNEL Long term Inhalation DNELLong term permai thalation DNELbw/day' Canger Long term Dermai 1611 mg/ kg bw/day OutkersSystemic Systemic population population population population population population DNEL Long term Oral DNEL Long term Oral 149 mg/kg General DNEL Long term Tra 57 mg/ General Caneral Caneral Caneral DNEL Long term Tra 57 mg/ General DNEL Long term Tra 57 mg/ General DNEL Long term Tra 57 mg/ General DNEL Long term Tra 57 mg/ MorkersSystemic Systemic population General Doublation Doublation DNEL Long term Tra 57 mg/ General DNEL Long term Tra 57 mg/ MorkersSystemic Systemic population Caneral Doublation Doublation mg/mg/ General Doublation Caneral Doublation MorkersSystemic Systemic population2.Methoxy-1-methylethyl acetateDNEL DNEL Long term Cral Inhalation DNEL Long term Cral DNEL Long term Cral DNEL Long term Cral DNEL Long term Dermal 300 mg/kg DNEL Long term Cral DNEL Long term Dermal 320 mg/kg DNEL Long term Dermal DNEL Long term Dermal 320 mg/kg DNEL Long term Dermal DNEL Long term Der							
NEL inhalation polletLong term inhalation pollet600 mg/m² inhalation horesWorkers systemicSystemic systemicVaphtha (petroleum), hydrotreated ightDNEL Long term Oral DNEL Long term Oral1.9 mg/m² bw/day General bw/dayGeneral population population General Divel Long term Oral3.9 mg/m² General population General Local Divels Local tinhalation Divels Lorg term Oral149 mg/kg General population General Ceneral Ceneral Local Divels Local tinhalation Divels Divels Divels Long term Oral Divels Divels Divels Short term Divels Short term Divels Short term Divels Short term Divels Divels Short term Divels Divels Divels Short term Divels Divels Divels Short term Divels		DNEL	Long term Dermal			Systemic	
Naphtha (petroleum), hydrotreated ightDNEL Long term Dermal Long term Dermal Inhalation DNEL Long term Carl Inhalation DNEL Long term Carl DNEL Long term Carl DNEL Long term Carl DNEL Long term Carl Habation DNEL Long term Carl DNEL Long term Carl DNEL Long term Carl DNEL Long term Carl DNEL Long term Carl DNEL Long term Carl DNEL Long term Carl DNEL Short term DNEL Short term Inhalation DNEL DNEL Short term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal Systemic population Carl Workers Systemic Morkers Systemic Morkers Systemic DNEL Long term Dermal DNEL Long term De							
Naphtha (petroleum), hydrotreated ightDNELLong term Long term1161 mg/ bw/day 0.41 mg/m² General populationSystemic Systemic populationNAPhtha (petroleum), hydrotreated ightDNELLong term Long term Oral1.9 mg/m² MorkersGeneral population populationSystemic populationDNELLong term Oral Inhalation149 mg/kg Beneral bw/dayGeneral populationSystemic populationDNELLong term Dermai Inhalation149 mg/kg Beneral bw/dayGeneral populationLocal populationDNELLong term Inhalation87.5 mg/ m³General populationLocal populationDNELShort term Inhalation1066.67 m³WorkersLocal populationDNELShort term Inhalation1066.67 m³WorkersSystemic populationDNELLong term Dermal Inhalation300 mg/kg populationGeneral populationSystemic populationDNELLong term Dermal Inhalation300 mg/kg populationGeneral populationLocal populationDNELLong term Dermal Inhalation30 mg/kg populationGeneral populationSystemic populationDNELLong term Dermal Inhalation30 mg/kg populationGeneral populationSystemic populationDNELLong term Dermal Inhalation30 mg/kg populationGeneral populationSystemic populationDNELLong term Dermal Inhalation30 mg/kg populationGenera		DNEL	Long term	600 mg/m³	Workers	Systemic	
Apphtha (petroleum), hydrotreated ightDNEL Long term inhalation DNELLong term inhalation Long term Oral0.41 mg/m² MV General populationSystemic populationDNEL Long term Oral1.9 mg/m² HV General DNEL Inhalation DNEL Long term Dermal Inhalation DNEL Long term Dermal Inhalation DNEL Long term Inhalation DNEL Long term Inhalation MV General MV General MV General MV General DNEL Long term Inhalation MV General MV General DNEL Short term Inhalation MV General MV General MV General MV General MV General DNEL Long term Inhalation MV General MV General MV General MV General MV General DNEL Long term DNEL Long term Dermal DNEL Long term Dermal DNEL<							
Naphta (petroleum), hydrotreated DNEL Long term inhalation 0.41 mg/m² General Workers Systemic Systemic ight DNEL Long term Oral 1.9 mg/m² General population Systemic DNEL Long term Oral 1.49 mg/kg General population Systemic DNEL Long term Dermal 149 mg/kg General population Systemic DNEL Long term Dermal 149 mg/kg General population Systemic DNEL Short term 640 mg/m² General population Local DNEL Short term 1152 mg/ Workers Local Inhalation mg/m² General Systemic DNEL Short term 1152 mg/ General Systemic Inhalation mg/m² General Systemic Jopulation DNEL Long term Dermal 300 mg/kg General Systemic Inhalation mg/m² General Systemic Jopulation Jopulation DNEL Long term Dermal 30 mg/m² <		DNEL	Long term Dermal		Workers	Systemic	
ight a ward of the second seco					a .		
DNEL Long term Inhalation 1.9 mg/m³ Workers Systemic DNEL Long term Oral 149 mg/kg bw/day General population Systemic DNEL Long term Dermal 149 mg/kg bw/day General population Systemic DNEL Long term 178.57 mg/ inhalation General population Systemic DNEL Short term 640 mg/m³ General population Local DNEL Short term 1066.67 Workers Local Inhalation m³ gopulation Systemic DNEL Short term 1266.4 mg/ inhalation Workers Systemic DNEL Short term 1286.4 mg/ inhalation Workers Systemic DNEL Long term 13 mg/m³ General population Local population DNEL Long term 13 mg/m³ General population Systemic DNEL Long term 13 mg/m³ General population Systemic DNEL Long term 13 mg/m³ General population Systemic		DNEL		0.41 mg/m ³		Systemic	
ProbabilityImplaintion Long term OralLong term Oral bw/dayGeneral populationSystemic populationDNELLong term Dermal Inhalation Inhalation DNELLong term Dermal 149 mg/kgGeneral GeneralSystemic populationDNELLong term Inhalation Inhalation DNELShort term Inhalation m³General GeneralLocal populationDNELShort term Inhalation Inhalation DNELShort term Inhalation m³General gopulationLocal populationDNELShort term Inhalation Inhalation DNELShort term Inhalation m³General gopulationSystemic populationDNELLong term Dermal Inhalation DNELCong term Dermal Inhalation DNELGeneral populationSystemic population2-Methoxy-1-methylethyl acetateDNEL Long term Dermal Inhalation DNELLong term Dermal 33 mg/m³General General gopulationSystemic population2-Methoxy-1-methylethyl acetateDNEL Long term Dermal Inhalation DNEL Long term Dermal36 mg/kg WorkersGeneral gopulationSystemic population2-Methoxy-1-methylethyl acetateDNEL Long term Dermal Inhalation DNEL Long term Dermal320 mg/kg WorkersGeneral gopulationSystemic populationDNEL Long term Dermal Inhalation DNEL DNEL Long term Dermal220 mg/kg WorkersGeneral gopulationSystemic populationDNEL DNEL Long term Dermal Inhalation 	ight						
DNELLong term Oral149 mg/kg bw/dayGeneral populationSystemic populationDNELLong term149 mg/kg bw/dayGeneral populationSystemic populationDNELLong term149 mg/kg bw/dayGeneral populationLocalDNELShort term640 mg/m³ m³General populationLocalDNELShort term1066.67 InhalationWorkersLocalDNELShort term1152 mg/ m³General populationSystemicDNELShort term1286.4 mg/ m³WorkersSystemicDNELShort term1286.4 mg/ WorkersSystemicDNELLong term Dermal Inhalation300 mg/kg WorkersWorkersSystemicDNELLong term Dermal Inhalation300 mg/kg Bow/dayGeneral populationSystemicDNELLong term33 mg/m³ GeneralGeneral populationSystemicDNELLong term Oral36 mg/kg Bow/dayGeneral populationSystemicDNELLong term Oral320 mg/kg Bow/dayGeneral populationSystemicDNELLong term Dermal Inhalation227 mg/m³General populationSystemicDNELLong term Dermal Inhalation260 mg/m³ GeneralGeneral populationLocal populationDNELLong term Inhalation260 mg/m³ GeneralGeneral populationLocal populationDNELLong term Inhalation225 mg/m³ GeneralGene		DNEL		1.9 mg/m³	Workers	Systemic	
Vordag Dopulation Systemic population DNEL Long term Dermal bw/day General population Systemic population DNEL Long term 178.57 mg/ General Local DNEL Short term 640 mg/m³ General Local Inhalation m³ 640 mg/m³ General Local Inhalation m³ General Local Inhalation DNEL Short term 1162 mg/m³ General Systemic Inhalation m³ General Systemic Inhalation DNEL Short term 1266.4 mg/ Workers Systemic Inhalation m³ General Systemic Inhalation m³ gopulation Systemic DNEL Long term Dermal 300 mg/kg Workers Systemic DNEL Long term 33 mg/m³ General Systemic DNEL Long term 375 mg/m Workers Systemic DNEL Long term <					a .		
DNEL polation inhalation DNEL inhalation DNEL inhalation DNEL inhalation DNEL 		DNEL	Long term Oral			Systemic	
bw/daypopulation General populationLocal populationDNELLong term Inhalation178.57 mg/ m² populationLocal populationDNELShort term640 mg/m²General populationLocalDNELShort term1066.67 InhalationWorkersLocalDNELShort term1152 mg/ InhalationGeneral m²SystemicDNELShort term1152 mg/ InhalationGeneral populationSystemicDNELShort term1286.4 mg/ m²WorkersSystemicDNELShort term1286.4 mg/ m²WorkersSystemicDNELShort term1286.4 mg/ m²WorkersSystemicDNELLong term330 mg/m³General populationLocalDNELLong term138 mg/m³General populationLocalDNELLong term33 mg/m³General populationSystemicDNELLong term Oral36 mg/kg bw/dayGeneral populationSystemicDNELLong term Oral320 mg/m²General populationSystemicDNELLong term Dermal Inhalation320 mg/m²General populationSystemicDNELLong term Dermal Inhalation260 mg/m²General populationLocal populationDNELLong term Dermal Inhalation260 mg/m²General populationLocal populationDNELLong term Dermal Inhalation260 mg/m²General populationLocal pop							
DNEL Inhalation Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation ModelDesci Local Local Model M		DNEL	Long term Dermal			Systemic	
Inhalationm³ 640 mg/m³population General populationDNELShort term640 mg/m³General populationDNELLong term837.5 mg/ m³WorkersLocalDNELShort term1162 mg/m³General mg/m³Systemic populationDNELShort term1162 mg/ m³General populationSystemic populationDNELShort term1162 mg/ m³General populationSystemic populationDNELShort term1128 fail m³General populationSystemic populationDNELLong term Dermal Inhalation300 mg//g bw/dayWorkersSystemic populationDNELLong term Oral Inhalation36 mg//g bw/dayGeneral populationSystemic populationDNELLong term Dermal Inhalation320 mg/m³General populationSystemic populationDNELLong term Dermal Inhalation320 mg/m³General populationSystemic populationDNELLong term Dermal Inhalation320 mg/m³General populationSystemic populationDNELLong term Dermal Inhalation65.3 mg/m³General populationLocal populationSystemicInhalation260 mg/m³General populationLocal populationDNELLong term Dermal Inhalation260 mg/m³General populationLocal populationDNELLong term Oral Inhalation260 mg/m³General populationLocal population							
DNEL InhalationShort term Inhalation640 mg/m³ ipulationGeneral populationLocalDNEL InhalationLong term Inhalation837.5 mg/ m³WorkersLocalDNEL InhalationDNEL InhalationSoft term 1152 mg/ m³1066.67 general populationKorkersLocalDNEL InhalationShort term Inhalation1152 mg/ m³General populationSystemic populationDNEL InhalationDNEL InhalationLong term bw/day30 mg/kg bw/dayWorkersSystemic population2-Methoxy-1-methylethyl acetateDNEL Iong term InhalationLong term DNEL Iong term Inhalation33 mg/m³ general general bw/dayGeneral populationSystemic population2-Methoxy-1-methylethyl acetateDNEL Iong term InhalationLong term DNEL Iong term Inhalation33 mg/m³ general general bw/dayGeneral populationSystemic population2-Methoxy-1-methylethyl acetateDNEL Iong term InhalationLong term DNEL Iong term Inhalation320 mg/kg bw/dayGeneral general populationSystemic population2-Methoxy-1-methylethyl acetateDNEL Iong term Inhalation220 mg/kg bw/dayGeneral general populationSystemic population2-Methoxy-1-methylethyl acetateDNEL Iong term Dermal Inhalation320 mg/kg Beneral bw/dayGeneral general populationSystemic population2-Methoxy-1-methylethyl acetateDNEL Iong term Dermal <td></td> <td>DNEL</td> <td>5</td> <td></td> <td></td> <td>Local</td> <td></td>		DNEL	5			Local	
Inhalation Long term InhalationNet B37.5 mg/ 		DNE					
DNEL InhalationLong term inhalation87.5 mg/ m³Workers WorkersLocalDNEL InhalationDNEL Inhalation1066.67 mg/m³WorkersLocalDNEL InhalationDNEL Inhalation1152 mg/ populationGeneral populationSystemicDNEL InhalationStort term Inhalation1152 mg/ m³General populationSystemicDNEL InhalationDNEL InhalationLong term population300 mg/kg bw/dayWorkersSystemic2-Methoxy-1-methylethyl acetateDNEL InhalationLong term Inhalation33 mg/m³ generalGeneral populationSystemic population2-Methoxy-1-methylethyl acetateDNEL InhalationLong term Inhalation33 mg/m³ generalGeneral populationSystemic population2-Methoxy-1-methylethyl acetateDNEL InhalationLong term Inhalation33 mg/m³ generalGeneral populationSystemic populationDNEL InhalationLong term Dermal Inhalation320 mg/kg bw/dayGeneral populationSystemic populationDNEL InhalationDNEL InhalationShort term Inhalation260 mg/m³General populationLocal populationDNEL InhalationDNEL InhalationLong term Oral Inhalation260 mg/m³ GeneralLocal populationLocal populationDNEL InhalationDNEL InhalationLong term Oral Inhalation260 mg/m³ GeneralSystemic populationDNEL Inhalati		DNEL		640 mg/m ³		Local	
Inhalationm³ 1066.67WorkersLocalDNELShort term1166.67WorkersLocalDNELShort term1152 mg/ populationGeneral populationSystemicDNELShort term1264.4 mg/WorkersSystemicDNELLong term Dermal300 mg/kg bw/dayWorkersSystemicDNELLong term33 mg/m³General populationLocalDNELLong term33 mg/m³General populationSystemicDNELLong term Oral36 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Oral36 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Dermal320 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Dermal Inhalation320 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Dermal Inhalation796 mg/kg bw/dayWorkersSystemic populationDNELLong term Inhalation260 mg/m³General populationLocal populationDNELLong term Inhalation221 mg/m³General general populationSystemic populationDNELLong term Inhalation221 mg/m³General general populationSystemic populationDNELLong term Oral12.5 mg/kg general populationGeneral populationSystemic populationDNELLong term Dermal Inhalation<		DNE		007 5			
DNEL Inhalation ImplicibilityShort term inhalation mg/m31066.67 mg/m3WorkersLocalDNEL InhalationDNEL Short term Inhalation1152 mg/ m3General populationSystemicDNEL InhalationDNEL Inhalation1162 mg/ m3General populationSystemicDNEL InhalationDNEL Inhalation1162 mg/ m3WorkersSystemicDNEL InhalationDNEL InhalationLong term population33 mg/m3 populationGeneral populationLocalDNEL InhalationDNEL InhalationLong term population33 mg/m3 populationGeneral populationSystemic populationDNEL InhalationLong term Oral Inhalation36 mg/kg bw/dayGeneral populationSystemic populationDNEL InhalationLong term Dermal Inhalation320 mg/kg Bow/dayGeneral populationSystemicDNEL InhalationLong term Dermal Inhalation320 mg/kg Bow/dayGeneral populationSystemicDNEL InhalationDNEL InhalationCong term InhalationGeneral populationSystemicDNEL InhalationDNEL InhalationSort term populationCocal populationLocal populationDNEL InhalationLong term Inhalation221 mg/m3General gopulationSystemic populationDNEL InhalationLong term Oral Inhalation12.5 mg/kg gopulationGeneral populationSystemic population <tr< td=""><td></td><td>DNEL</td><td>-</td><td>-</td><td>vvorkers</td><td>Local</td><td></td></tr<>		DNEL	-	-	vvorkers	Local	
NELInhalation Short term Inhalationmg/m³ 1152 mg/ populationGeneral populationSystemic2-Methoxy-1-methylethyl acetateDNELShort term Long term Dermal1286.4 mg/ 300 mg/kgWorkersSystemic2-Methoxy-1-methylethyl acetateDNELLong term Dermal Inhalation DNEL300 mg/kg BowldayWorkersSystemic2-Methoxy-1-methylethyl acetateDNELLong term Inhalation DNEL33 mg/m³General population populationLocal populationDNELLong term Inhalation DNEL36 mg/kg BowldayGeneral populationSystemic populationDNELLong term Oral36 mg/kg Bw/day DNELGeneral populationSystemic populationDNELLong term Dermal Inhalation DNEL225 mg/m³General Bw/day WorkersSystemic LocalDNELLong term Dermal Inhalation Inhalation DNELSort term Domg260 mg/m³General populationLocal populationDNELShort term Inhalation Inhalation DNELScong term Bw/dayGeneral populationSystemic LocalDNELLong term Inhalation Inhalation Inhalation221 mg/m³General gopulationSystemic LocalDNELLong term Inhalation Inhalation221 mg/m³General gopulationSystemic LocalDNELLong term Inhalation Inhalation12.5 mg/g GeneralGeneral populationSystemic LocalDNELLong term Inhalation Inhalation		DNE					
DNEL InhalationShort term inhalation1152 mg/ m³General population mold/g WorkersSystemic2-Methoxy-1-methylethyl acetateDNELLong term Dermal300 mg/kg bw/day InhalationWorkersSystemic2-Methoxy-1-methylethyl acetateDNELLong term Inhalation33 mg/m³ General populationGeneral populationLocal population2-Methoxy-1-methylethyl acetateDNELLong term Inhalation33 mg/m³ GeneralGeneral populationSystemicDNELLong term Oral Inhalation36 mg/kg Bw/dayGeneral populationSystemicDNELLong term Oral Inhalation320 mg/kg Bw/dayGeneral populationSystemicDNELLong term Dermal Inhalation320 mg/kg BorklaGeneral populationSystemicDNELLong term Dermal Inhalation320 mg/kg BorklaGeneral populationLocal populationDNELLong term Dermal Inhalation796 mg/kg BorklaWorkersSystemic populationDNELLong term Inhalation260 mg/m³ BorklaGeneral Local populationLocal populationDNELLong term Inhalation221 mg/m³ BorklaGeneral BorklaLocal populationDNELLong term Oral Inhalation12.5 mg/ BorklaGeneral BorklaSystemic SystemicDNELLong term Oral Inhalation12.5 mg/ BorklaGeneral BorklaSystemic SystemicDNELLong term Oral Inhalation<		DNEL			vvorkers	Local	
Provide Production Production Production DNELInhalation Short term Inhalation DNEL Long term Dermalm³ 1286.4 mg/ Workerspopulation Systemic bw/day General population General population DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term DNEL Long term DNEL Long term Dermal DNEL Long term Dermal DNEL Lo					0	O un to un in	
DNEL Inhalation DNELShort term Inhalation DNEL1286.4 mg/ m³ 300 mg/kg bw/dayWorkers SystemicSystemic2-Methoxy-1-methylethyl acetateDNEL DNELLong term Dermal300 mg/kg bw/dayWorkersSystemicDNEL Inhalation DNELLong term Inhalation DNEL233 mg/m³ General population General populationGeneral population General populationSystemicDNEL Inhalation DNELLong term Inhalation DNEL275 mg/m³ WorkersGeneral population Systemic populationSystemic populationDNEL Inhalation DNELLong term Dermal Inhalation DNEL275 mg/m³ WorkersGeneral population WorkersSystemic populationQueueDNEL Inhalation Inhalation DNELLong term Dermal Inhalation DNEL260 mg/m³ General populationGeneral population Inhalation DNELLocal population WorkersLocal populationQueueDNEL Inhalation Inhalation DNELShort term Inhalation DNEL260 mg/m³ General populationGeneral population General populationSystemic populationDNEL Inhalation Inhalation DNEL Inhalation DNEL Inhalation DNEL Inhalation DNEL Long term Oral221 mg/m³ UVerkersGeneral Systemic populationSystemic Systemic populationDNEL Inhalation Inhalation Inhalation DNEL Inhalation DNEL Inhalation DNEL Inhalation DNEL Inhalation DNEL Long term Oral Inhalation DNEL Inhalation DNEL <b< td=""><td></td><td>DNEL</td><td></td><td></td><td></td><td>Systemic</td><td></td></b<>		DNEL				Systemic	
2-Methoxy-1-methylethyl acetate DNEL Long term Dermal 300 mg/kg 300 mg/kg bw/day Workers Systemic 2-Methoxy-1-methylethyl acetate DNEL Long term Inhalation 33 mg/m³ General population Local population DNEL Long term Inhalation 33 mg/m³ General population Systemic DNEL Long term Oral 36 mg/kg bw/day General population Systemic DNEL Long term Oral 320 mg/kg bw/day General population Systemic DNEL Long term Dermal 320 mg/kg bw/day General population Systemic DNEL Long term Dermal 320 mg/kg bw/day Workers Systemic DNEL Long term Dermal 320 mg/kg bw/day Workers Systemic DNEL Long term Dermal 320 mg/kg bw/day Workers Systemic DNEL Long term Dermal 796 mg/kg bw/day Workers Systemic DNEL Long term Dermal 260 mg/m³ General population Local population DNEL Long term Oral 12.5 mg/kg bpopulation General population Systemic DNEL Long term Derm						Svetomio	
DNELLong term Dermal300 mg/kg bw/dayWorkersSystemic2-Methoxy-1-methylethyl acetateDNELLong term Inhalation33 mg/m³General populationLocal populationDNELLong term Inhalation33 mg/m³General generalSystemic populationDNELLong term Inhalation36 mg/kg bw/dayGeneral populationSystemicDNELLong term Oral36 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal320 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal320 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal320 mg/kg bw/dayGeneral populationSystemicDNELShort term Inhalation796 mg/kg bw/dayWorkersSystemicDNELShort term Inhalation260 mg/m³General populationLocalDNELShort term Inhalation260 mg/m³General populationLocalDNELLong term Oral12.5 mg/ kg bw/dayGeneral generalSystemic populationDNELLong term Oral Inhalation12.5 mg/ kg bw/dayGeneral generalSystemic populationDNELLong term Dermal Inhalation125 mg/kg bw/dayGeneral general populationSystemic populationDNELLong term Dermal Inhalation125 mg/kg bw/dayGeneral generalSystemic SystemicDNELLong term Dermal I		DNEL			vvorkers	Systemic	
2-Methoxy-1-methylethyl acetate DNEL DNEL DNEL DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term DNEL Long term DNEL DNEL Long term 260 mg/m ³ General population General population General population General DNEL Long term DNEL DNEL Long term DNEL Long term Dermal DNEL Long term Dermal DNEL DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL DNEL Long term Dermal DNEL DNEL Long term Dermal DNEL Long term Dermal DNEL DNEL Long term Dermal DNEL DNEL Long term Dermal DNEL Long term Dermal DNEL DN					Workoro	Svetomio	
2-Methoxy-1-methylethyl acetate DNEL Long term Inhalation 33 mg/m³ General population Local DNEL Long term Inhalation 33 mg/m³ General population Systemic DNEL Long term Oral 36 mg/kg bw/day General population Systemic DNEL Long term Oral 36 mg/kg bw/day General population Systemic DNEL Long term Dermal 320 mg/kg bw/day General population Systemic DNEL Long term Dermal 320 mg/m³ General population Systemic DNEL Long term Dermal 320 mg/m³ General population Systemic DNEL Long term Dermal 796 mg/kg bw/day Workers Systemic DNEL Long term 260 mg/m³ General population Local DNEL Short term 260 mg/m³ General population Local DNEL Long term 260 mg/m³ General population Local DNEL Long term 210 mg/m³ General population Systemic DNEL Long term 221 mg/m³ General population Systemic		DNEL	Long term Dermai		workers	Systemic	
ViewInhalationDescriptionpopulationDNELLong term33 mg/m³GeneralSystemicInhalationDNELLong term Oral36 mg/kgGeneralSystemicDNELLong term275 mg/m³WorkersSystemicDNELLong term275 mg/m³WorkersSystemicDNELLong term Dermal320 mg/kgGeneralSystemicDNELLong term Dermal320 mg/kgGeneralSystemicDNELLong term Dermal320 mg/kgGeneralSystemicDNELLong term Dermal796 mg/kgWorkersLocalDNELLong term Dermal796 mg/kgWorkersSystemicDNELLong term65.3 mg/m³GeneralLocalpopulationDNELShort term260 mg/m³GeneralLocalpopulationDNELShort term260 mg/m³GeneralSystemicInhalationDNELLong term221 mg/m³WorkersLocalDNELLong term12.5 mg/GeneralSystemicDNELLong term Oral12.5 mg/kgGeneralSystemicDNELLong term Dermal125 mg/kgGeneralSystemicDNELLong term Dermal125 mg/kgGeneralSystemicDNELLong term Dermal125 mg/kgGeneralSystemicDNELLong term Dermal125 mg/kgGeneralSystemicDNELLong term Dermal212 mg/kgWorkersSystemic <td>Mathawy 1 mathylathyl apatata</td> <td></td> <td>Long torm</td> <td></td> <td>Conorol</td> <td></td> <td></td>	Mathawy 1 mathylathyl apatata		Long torm		Conorol		
DNELLong term Inhalation33 mg/m³General opulationSystemicDNELLong term Oral36 mg/kg bw/dayGeneral opulationSystemicDNELLong term Oral275 mg/m³General populationSystemicDNELLong term Dermal320 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal320 mg/kg bw/dayGeneral populationSystemicDNELShort term Inhalation550 mg/m³WorkersLocalDNELLong term Dermal796 mg/kg bw/dayWorkersSystemicDNELLong term Dermal796 mg/kg bw/dayWorkersSystemicDNELLong term Dermal796 mg/kg bw/dayWorkersSystemicDNELLong term Dermal260 mg/m³General populationLocal populationDNELShort term Inhalation260 mg/m³General populationSystemic populationDNELLong term Oral12.5 mg/ kg bw/dayGeneral populationSystemic populationDNELLong term Oral12.5 mg/ kg bw/dayGeneral populationSystemic populationDNELLong term Dermal125 mg/kg populationSystemic populationSystemic populationDNELLong term Dermal125 mg/kg populationSystemic populationSystemic populationDNELLong term Dermal125 mg/kg populationSystemic populationSystemic populationDNELLong term Dermal		DNEL	v	55 mg/m		LUCAI	
Inhalation Long term OralDesc Sec Bw/daypopulation General populationSystemic SystemicDNELLong term Inhalation275 mg/m³General WorkersSystemicDNELLong term Dermal320 mg/kg bw/dayGeneral populationSystemicDNELShort term Inhalation550 mg/m³General WorkersSystemicDNELShort term Inhalation550 mg/m³WorkersLocalDNELLong term Dermal796 mg/kg bw/dayWorkersSystemicDNELLong term Dermal796 mg/kg bw/dayWorkersSystemicDNELLong term Inhalation65.3 mg/m³General populationLocalDNELShort term Inhalation260 mg/m³General populationLocal populationDNELShort term Inhalation260 mg/m³General populationSystemic populationDNELLong term Oral Inhalation12.5 mg/kg populationGeneral populationSystemic populationDNELLong term Oral Inhalation12.5 mg/kg populationGeneral populationSystemic populationDNELLong term Dermal Inhalation12.5 mg/kg populationSystemic populationSystemic populationDNELLong term Dermal Inhalation12.5 mg/kg populationSystemic populationSystemic populationDNELLong term Dermal Inhalation12.5 mg/kg populationSystemic populationSystemic populationDNEL <td></td> <td></td> <td></td> <td>33 mg/m^3</td> <td></td> <td>Systemic</td> <td></td>				33 mg/m^3		Systemic	
DNELLong term Oral36 mg/kg bw/dayGeneral populationSystemicDNELLong term inhalation275 mg/m³WorkersSystemicDNELLong term Dermal320 mg/kg bw/dayGeneral populationSystemicDNELShort term inhalation550 mg/m³General populationSystemicDNELShort term inhalation796 mg/kg bw/dayWorkersLocalDNELLong term Dermal796 mg/kg bw/dayWorkersSystemicDNELLong term Dermal796 mg/kg bw/dayGeneral populationLocalDNELShort term inhalation260 mg/m³General populationLocal populationDNELShort term inhalation260 mg/m³General populationLocal populationDNELLong term Oral inhalation12.5 mg/kg g bw/dayGeneral populationSystemic populationDNELLong term Oral inhalation12.5 mg/kg g bw/dayGeneral populationSystemic populationDNELLong term Dermal125 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Dermal125 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Dermal125 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Dermal125 mg/kg bw/daySystemic populationSystemic populationDNELLong term Dermal inhalation125 mg/kg bw/day <td></td> <td>DINLL</td> <td></td> <td>55 mg/m</td> <td></td> <td>Systemic</td> <td></td>		DINLL		55 mg/m		Systemic	
KyleneDNEL Inhalation Inhalation DNELLong term Inhalation Inhalation DNELbw/day 275 mg/m³ 275 mg/m³population WorkersSystemic Systemic population WorkersKyleneDNEL Inhalation DNELShort term Inhalation DNELSoft term Inhalation DNELGeneral population WorkersSystemic LocalKyleneDNEL Inhalation DNELLong term Dermal Inhalation DNEL796 mg/kg bw/day General population General population General populationLocal population General population General populationDNEL Inhalation DNELShort term Inhalation DNEL260 mg/m³ General populationGeneral Systemic populationDNEL Inhalation DNELLong term Oral Inhalation DNEL12.5 mg/ General populationGeneral Systemic populationDNEL Inhalation DNELLong term Oral Inhalation DNEL12.5 mg/kg General populationGeneral Systemic populationDNEL Inhalation DNELLong term Dermal Inhalation DNEL125 mg/kg General populationSystemic Systemic populationDNEL Inhalation DNELLong term Dermal Inhalation DNEL125 mg/kg General SystemicSystemic SystemicDNEL Inhalation DNELLong term Dermal Inhalation DNEL125 mg/kg WorkersSystemic SystemicDNEL Inhalation DNELLong term Dermal Inhalation DNEL125 mg/kg WorkersSystemic Systemic				36 ma/ka		Systemic	
DNELLong term Inhalation275 mg/m³WorkersSystemicDNELLong term Dermal320 mg/kg bw/dayGeneral populationSystemicDNELShort term Inhalation550 mg/m³WorkersLocalDNELLong term Dermal796 mg/kg bw/dayWorkersSystemicDNELLong term Dermal65.3 mg/m³General populationLocalDNELShort term Inhalation260 mg/m³General populationLocalDNELShort term Inhalation260 mg/m³General populationLocalDNELShort term Inhalation260 mg/m³General populationLocalDNELShort term Inhalation260 mg/m³General populationSystemicDNELLong term Inhalation221 mg/m³WorkersLocalDNELLong term Oral12.5 mg/ kg bw/dayGeneral populationSystemicDNELLong term Dermal125 mg/kg gopulationSystemicDNELLong term Dermal125 mg/kg populationSystemicDNELLong term Dermal125 mg/kg populationSystemicDNELLong term Dermal125 mg/kg populationSystemicDNELLong term Dermal125 mg/kg populationSystemic		DIVLL	Long term oral			Oysternie	
KyleneInhalation Long term Dermal320 mg/kg bw/dayGeneral populationSystemicDNELShort term Inhalation550 mg/m³WorkersLocalDNELLong term Dermal796 mg/kg bw/dayWorkersSystemicDNELLong term Dermal796 mg/kg bw/dayWorkersSystemicDNELLong term Dermal796 mg/kg bw/dayWorkersSystemicDNELLong term Inhalation260 mg/m³General populationLocalDNELShort term Inhalation260 mg/m³General populationLocalDNELShort term Inhalation221 mg/m³General populationSystemicDNELLong term Oral Inhalation12.5 mg/ generalGeneral populationSystemicDNELLong term Oral Inhalation12.5 mg/kg generalGeneral populationSystemicDNELLong term Dermal125 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal125 mg/kg bw/dayGeneral populationSystemic			Long term	275 mg/m^3		Systemic	
DNELLong term Dermal320 mg/kg bw/dayGeneral populationSystemicDNELShort term Inhalation550 mg/m³WorkersLocalDNELLong term Dermal796 mg/kg bw/dayWorkersSystemicKyleneDNELLong term Inhalation65.3 mg/m³General populationLocalDNELShort term Inhalation260 mg/m³General populationLocalDNELShort term Inhalation260 mg/m³General populationLocalDNELShort term Inhalation260 mg/m³General populationSystemicDNELLong term Inhalation221 mg/m³WorkersLocalDNELLong term Oral12.5 mg/ kg bw/dayGeneral populationSystemicDNELLong term Dermal125 mg/kgGeneral populationSystemicDNELLong term Dermal125 mg/kgGeneral populationSystemicDNELLong term Dermal125 mg/kgGeneral populationSystemicDNELLong term Dermal125 mg/kgGeneral populationSystemicDNELLong term Dermal121 mg/kgSystemicSystemic		DITLE		270 mg/m	Wonkere	Cyclonic	
KyleneDNEL Inhalation DNELShort term Inhalation DNELbw/day 550 mg/m³population WorkersLocalKyleneDNEL DNELLong term Dermal796 mg/kg bw/dayWorkersSystemicDNEL Inhalation DNELLong term Inhalation DNEL65.3 mg/m³ General population General Inhalation DNELLocal population General populationLocalDNEL Inhalation DNELShort term Inhalation DNEL260 mg/m³ General populationGeneral population General populationLocalDNEL Inhalation DNELLong term Inhalation DNEL221 mg/m³ General populationSystemic populationDNEL Inhalation DNELLong term Oral Inhalation DNEL12.5 mg/ General populationGeneral Systemic populationDNEL Inhalation DNELLong term Dermal Inhalation Inhalation125 mg/kg Bw/dayGeneral Systemic populationDNEL Inhalation DNELLong term Dermal Inhalation125 mg/kg Bw/daySystemic SystemicDNEL Inhalation InhalationDNEL Long term Dermal125 mg/kg Bw/daySystemic Systemic		DNFI		320 ma/ka	General	Systemic	
DNELShort term Inhalation550 mg/m³WorkersLocalDNELLong term Dermal796 mg/kg bw/dayWorkersSystemicONELLong term Inhalation65.3 mg/m³General populationLocalDNELShort term Inhalation260 mg/m³General populationLocalDNELShort term Inhalation260 mg/m³General populationLocalDNELShort term Inhalation260 mg/m³General populationLocalDNELShort term Inhalation260 mg/m³General populationSystemic populationDNELLong term Inhalation221 mg/m³General populationSystemic populationDNELLong term Oral Inhalation12.5 mg/ general populationSystemic populationSystemic populationDNELLong term Dermal Inhalation125 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Dermal125 mg/kg bw/daySystemic populationSystemic SystemicDNELLong term Dermal212 mg/kg bw/dayWorkersSystemic						-)	
KyleneInhalation Long term Dermal796 mg/kg bw/dayWorkersSystemicDNELLong term Inhalation DNELShort term Inhalation65.3 mg/m³ General populationGeneral populationLocal populationDNELShort term Inhalation260 mg/m³ General populationGeneral populationLocal populationDNELShort term Inhalation260 mg/m³ General populationGeneral populationSystemic populationDNELLong term Inhalation221 mg/m³ General populationSystemic populationSystemic populationDNELLong term Oral Inhalation12.5 mg/g General populationGeneral Systemic populationSystemic populationDNELLong term Dermal Inhalation125 mg/kg General populationGeneral Systemic populationSystemic populationDNELLong term Dermal Inhalation125 mg/kg WorkersGeneral Systemic populationSystemic SystemicDNELLong term Dermal Inhalation125 mg/kg Bow/dayGeneral SystemicSystemic SystemicDNELLong term Dermal Inhalation125 mg/kg Bow/dayGeneral SystemicSystemic		DNEL	Short term			Local	
KyleneDNELLong term Dermal796 mg/kg bw/dayWorkersSystemicDNELLong term Inhalation65.3 mg/m³General populationLocalDNELShort term Inhalation260 mg/m³General populationLocalDNELShort term Inhalation260 mg/m³General populationLocalDNELShort term Inhalation260 mg/m³General populationSystemicDNELCong term Inhalation221 mg/m³WorkersLocalDNELLong term Inhalation12.5 mg/ g bw/dayGeneral populationSystemicDNELLong term Oral Inhalation12.5 mg/ g General populationSystemicDNELLong term Dermal125 mg/kg g General populationSystemicDNELLong term Dermal125 mg/kg g General populationSystemicDNELLong term Dermal125 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal122 mg/kg bw/dayWorkersSystemic				j			
KyleneDNELLong term Inhalationbw/dayGeneral populationLocalDNELShort term Inhalation260 mg/m³General populationLocalDNELShort term Inhalation260 mg/m³General populationLocalDNELShort term Inhalation260 mg/m³General populationSystemicDNELLong term Inhalation221 mg/m³WorkersLocalDNELLong term Inhalation221 mg/m³General populationSystemicDNELLong term Oral12.5 mg/ kg bw/dayGeneral populationSystemic populationDNELLong term Dermal125 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Dermal125 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Dermal125 mg/kg bw/dayGeneral populationSystemic population		DNEL		796 mg/kg	Workers	Systemic	
KyleneDNELLong term Inhalation65.3 mg/m³ general populationGeneral populationLocalDNELShort term Inhalation260 mg/m³General populationLocalDNELShort term Inhalation260 mg/m³General populationSystemicDNELShort term Inhalation260 mg/m³General populationSystemicDNELLong term Inhalation221 mg/m³WorkersLocalDNELLong term Oral12.5 mg/ kg bw/dayGeneral populationSystemicDNELLong term Dermal125 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal125 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal125 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal125 mg/kg bw/daySystemicSystemicDNELLong term Dermal125 mg/kg bw/daySystemicSystemic						,	
InhalationpopulationDNELShort term260 mg/m³GeneralInhalationDNELShort term260 mg/m³GeneralDNELShort term260 mg/m³GeneralSystemicInhalationDNELLong term221 mg/m³WorkersLocalDNELLong term12.5 mg/GeneralSystemicDNELLong term Oral12.5 mg/GeneralSystemicDNELLong term Oral12.5 mg/m³GeneralSystemicDNELLong term65.3 mg/m³GeneralSystemicDNELLong term Dermal125 mg/kgGeneralSystemicDNELLong term Dermal125 mg/kgGeneralSystemicDNELLong term Dermal212 mg/kgWorkersSystemicDNELLong term Dermal212 mg/kgWorkersSystemic	Kylene	DNEL	Long term		General	Local	
DNELShort term Inhalation260 mg/m³General populationLocalDNELShort term Inhalation260 mg/m³General populationSystemicDNELLong term Inhalation221 mg/m³WorkersLocalDNELLong term Inhalation221 mg/m³General populationSystemicDNELLong term Oral12.5 mg/ kg bw/dayGeneral populationSystemicDNELLong term Oral12.5 mg/ kg bw/dayGeneral populationSystemicDNELLong term Inhalation65.3 mg/m³General gopulationSystemicDNELLong term Dermal125 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal212 mg/kg bw/daySystemicSystemic	-			-			
DNELShort term Inhalation260 mg/m³General populationSystemicDNELLong term Inhalation221 mg/m³WorkersLocalDNELLong term Oral12.5 mg/ kg bw/dayGeneral populationSystemicDNELLong term Oral12.5 mg/ kg bw/dayGeneral populationSystemicDNELLong term Oral12.5 mg/ kg bw/dayGeneral populationSystemicDNELLong term Dermal125 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal125 mg/kg bw/dayGeneral populationSystemic		DNEL	Short term	260 mg/m ³	General	Local	
Inhalation Long term Inhalation221 mg/m³population WorkersLocalDNELLong term Oral12.5 mg/ kg bw/dayGeneral populationSystemic populationDNELLong term Inhalation65.3 mg/m³General populationSystemic populationDNELLong term Inhalation125 mg/kgGeneral populationSystemic populationDNELLong term Dermal125 mg/kgGeneral populationSystemic populationDNELLong term Dermal125 mg/kgGeneral populationSystemic populationDNELLong term Dermal125 mg/kgGeneral populationSystemic populationDNELLong term Dermal121 mg/kg bw/daySystemic			Inhalation	_	population		
DNELLong term Inhalation221 mg/m³WorkersLocalDNELLong term Oral12.5 mg/ kg bw/dayGeneral populationSystemic populationDNELLong term Inhalation65.3 mg/m³General populationSystemic populationDNELLong term Inhalation125 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Dermal125 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Dermal212 mg/kg bw/dayWorkersSystemic		DNEL	Short term	260 mg/m ³	General	Systemic	
InhalationInhalationDNELLong term Oral12.5 mg/ kg bw/dayGeneral populationDNELLong term65.3 mg/m³General populationDNELLong term125 mg/kgGeneral populationDNELLong term Dermal125 mg/kgGeneral populationDNELLong term Dermal125 mg/kgGeneral populationDNELLong term Dermal212 mg/kg bw/dayWorkersSystemicSystemic			Inhalation				
DNELLong term Oral12.5 mg/ kg bw/dayGeneral populationSystemicDNELLong term65.3 mg/m³General populationSystemicDNELLong term Dermal125 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal125 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal125 mg/kg bw/dayGeneral populationSystemic		DNEL		221 mg/m ³	Workers	Local	
DNELLong term Inhalationkg bw/day 65.3 mg/m³population General populationSystemic Systemic populationDNELLong term Dermal125 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Dermal125 mg/kg bw/dayGeneral populationSystemic populationDNELLong term Dermal212 mg/kg bw/dayWorkersSystemic							
DNELLong term Inhalation65.3 mg/m³General populationSystemicDNELLong term Dermal125 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal212 mg/kg bw/dayWorkersSystemic		DNEL	Long term Oral			Systemic	
InhalationpopulationDNELLong term Dermal125 mg/kgGeneralSystemicbw/daypopulationbw/dayVorkersSystemicDNELLong term Dermal212 mg/kgWorkersSystemic				kg bw/day		_	
DNELLong term Dermal125 mg/kgGeneral populationSystemicDNELLong term Dermal212 mg/kg bw/dayWorkersSystemic		DNEL		65.3 mg/m ³		Systemic	
DNELLong term Dermalbw/daypopulation212 mg/kgWorkersSystemicbw/daybw/daybw/day				105 5			
DNEL Long term Dermal 212 mg/kg Workers Systemic bw/day		DNEL	Long term Dermal			Systemic	
bw/day							
		DNEL	Long term Dermal		Workers	Systemic	
DNEL Long term 221 mg/m ³ Workers Systemic							
		DNEL	Long term	1221 mg/m^{3}	Workers	Systemic	

SUPREMO KLARLACK 3990-02 - All variants

		Inhalation			
	DNEL	Short term	442 mg/m ³	Workers	Local
		Inhalation	5		
	DNEL	Short term	442 mg/m ³	Workers	Systemic
		Inhalation	Ŭ		, , , , , , , , , , , , , , , , , , ,
Methyl methacrylate	DNEL	Long term Oral	8.2 mg/kg	General	Systemic
-		-	bw/day	population	-
	DNEL	Short term	208 mg/m ³	General	Local
		Inhalation		population	
	DNEL	Short term	416 mg/m ³	Workers	Local
		Inhalation			
	DNEL	Short term Dermal	1.5 mg/cm ²		Local
				population	
	DNEL	Long term Dermal	1.5 mg/cm ²	General	Local
				population	
	DNEL	Short term Dermal	1.5 mg/cm ²		Local
	DNEL	Long term Dermal	1.5 mg/cm ²	Workers	Local
	DNEL	Long term Dermal	8.2 mg/kg	General	Systemic
			bw/day	population	
	DNEL	Long term Dermal	13.67 mg/	Workers	Systemic
			kg bw/day		
	DNEL	Long term	74.3 mg/m ³	General	Systemic
	_ ./	Inhalation		population	
	DNEL	Long term	104 mg/m³	General	Local
		Inhalation		population	
	DNEL	Long term	208 mg/m ³	Workers	Local
		Inhalation			
	DNEL	Long term	348.4 mg/	Workers	Systemic
		Inhalation	m³		

PNECs

No PNECs available

8.2 Exposure controls	
Appropriate engineering controls	: Use only with adequate ventilation. Use process enclosures, local exhaust ventilation or other engineering controls to keep worker exposure to airborne contaminants below any recommended or statutory limits. The engineering controls also need to keep gas, vapour or dust concentrations below any lower explosive limits. Use explosion-proof ventilation equipment.
Individual protection meas	<u>ires</u>
Hygiene measures	: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.
Eye/face protection	: Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: chemical splash goggles.
Skin protection	
Hand protection	: Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated.
	Recommendations : Wear suitable gloves tested to EN374.
	< 1 hour (breakthrough time): Nitrile gloves. thickness > 0.3 mm
Date of issue/Date of revision	: 20/12/2023 Date of previous issue : No previous validation Version : 1 9/19

SECTION 8: Exposure controls/personal protection

	1 - 4 hours (breakthrough time): $4H$ / Silver Shield® gloves.
Body protection	: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. When there is a risk of ignition from static electricity, wear anti-static protective clothing. For the greatest protection from static discharges, clothing should include anti-static overalls, boots and gloves. Refer to European Standard EN 1149 for further information on material and design requirements and test methods.
Other skin protection	: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
Respiratory protection	: Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other importan aspects of use.
	Filter type: A
	Filter type (spray application): A P
Environmental exposure controls	: Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

SECTION 9: Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

9.1 Information on basic physical and chemical properties

<u>Appearance</u>	
Physical state	: Liquid.
Colour	: Various
Odour	: Slight
Odour threshold	: Not available.
Melting point/freezing point	: Not available.
Initial boiling point and boiling range	:

Ingredient name		°C	°F	Method	
Ethyl acetate		77.1	170.8		
Butanone		79.59	175.3		
Flammability : Not avai		ilable.	·		
Lower and upper explosion : Lower: 0.		0.8%			

Upper: 11.5% limit

Flash point

: Closed cup: -1°C (30.2°F)

2

Auto-ignition temperature

Ingredient name			°C		°F		Method			
Naphtha (petroleum), hydrotreated light		280 to 470		536 to 878		DIN EN 14522				
2-Methoxy-1-methylethyl acetate			333		631.4		DIN 51794			
Decomposition temperature	:	Not avai	ilable.							
н	1	Not app	licable.							
Viscosity : Not ava			ilable.							
Solubility(ies)	:									
Not available.										
Solubility in water	:	Not avai	ilable.							
Partition coefficient: n-octanol/ water	:	Not app	licable.							
ate of issue/Date of revision	: 20	0/12/2023	Date of pr	evious iss	ue	: No previo	ous validation	Version	:1	10/19

SUPREMO KLARLACK 3990-02 - All variants

SECTION 9: Physical and chemical properties

2

Vapour pressure

	Va	apour Press	sure at 20°C	V	Vapour pressure at 50°C		
Ingredient name	mm Hg	kPa	Method	mm Hg	kPa	Method	
Ethyl acetate	81.59163	10.9					
Butanone	78.7564	10.5					
Relative density	: Not	available.	!				
Density	: 0.9	g/cm³					
/apour density	: Not	available.					
Explosive properties	: Not	available.					
Oxidising properties	: Not	available.					
Particle characteristics							
Median particle size	: Not	applicable.					

SECTION 10: Stability and reactivity

10.1 Reactivity	:	No specific test data related to reactivity available for this product or its ingredients.
10.2 Chemical stability	:	The product is stable.
10.3 Possibility of hazardous reactions	:	Under normal conditions of storage and use, hazardous reactions will not occur.
10.4 Conditions to avoid	:	Avoid all possible sources of ignition (spark or flame). Do not pressurise, cut, weld, braze, solder, drill, grind or expose containers to heat or sources of ignition.
10.5 Incompatible materials	:	Reactive or incompatible with the following materials: oxidising materials
10.6 Hazardous decomposition products	:	Under normal conditions of storage and use, hazardous decomposition products should not be produced.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Acute toxicity

Product/ingredient name	Result	Species	Dose	Exposure
n-Butyl acetate	LC50 Inhalation Vapour	Rat	0.74 mg/l	4 hours
	LD50 Dermal	Rabbit	14112 mg/kg	-
	LD50 Oral	Rat	10760 mg/kg	-
Ethyl acetate	LD50 Oral	Rat	5620 mg/kg	-
Butanone	LD50 Dermal	Rabbit	6480 mg/kg	-
	LD50 Oral	Rat	2737 mg/kg	-
2-Methoxy-1-methylethyl	LD50 Dermal	Rabbit	>5 g/kg	-
acetate				
	LD50 Oral	Rat	8532 mg/kg	-
Xylene	LC50 Inhalation Vapour	Rat	21.7 mg/l	4 hours
	LD50 Oral	Rat	4300 mg/kg	-
Methyl methacrylate	LC50 Inhalation Vapour	Rat	78000 mg/m ³	4 hours
· ·	LD50 Dermal	Rabbit	>5 g/kg	-
	LD50 Oral	Rat	7872 mg/kg	-

Acute toxicity estimates

2023 Date of previous issue

SECTION 11: Toxicological information

Route	ATE value
Dermal	29100.53 mg/kg
Inhalation (vapours)	291.01 mg/l

Irritation/Corrosion

Product/ingredient name	Result	Species	Score	Exposure	Observation
n-Butyl acetate	Eyes - Moderate irritant	Rabbit	-	100 mg	-
-	Skin - Moderate irritant	Rabbit	-	24 hours 500	-
				mg	
Butanone	Skin - Mild irritant	Rabbit	-	24 hours 14	-
				mg	
	Skin - Moderate irritant	Rabbit	-	24 hours 500	-
Yulono.	Even Mild irritent	Rabbit		mg	
Xylene	Eyes - Mild irritant Eyes - Severe irritant	Rabbit	-	87 mg 24 hours 5	-
	Lyes - Severe initalit	Tabbit	-	mg	-
	Skin - Mild irritant	Rat	-	8 hours 60 uL	-
	Skin - Moderate irritant	Rabbit	-	100 %	-
	Skin - Moderate irritant	Rabbit	-	24 hours 500	-
				mg	
Conclusion/Summary	: Based on available data, th	ne classification of	riteria are	not met.	
<u>Sensitisation</u>					
Conclusion/Summary	: May cause an allergic skin	reaction.			
<u>Mutagenicity</u>					
Conclusion/Summary	: Based on available data, th	ne classification o	riteria are	not met.	
Carcinogenicity					

Conclusion/Summary : Based on available data, the classification criteria are not met.

Conclusion/Summary : Based on available data, the classification criteria are not met.

Teratogenicity

Reproductive toxicity

Conclusion/Summary : Based on available data, the classification criteria are not met.

Specific target organ toxicity (single exposure)

Product/ingredient name	Category	Route of exposure	Target organs
n-Butyl acetate	Category 3	-	Narcotic effects
Ethyl acetate	Category 3	-	Narcotic effects
Butanone	Category 3	-	Narcotic effects
Xylene	Category 3	-	Respiratory tract irritation
Methyl methacrylate	Category 3	-	Respiratory tract irritation

Specific target organ toxicity (repeated exposure)

Product/ingredient name	Category	Route of exposure	Target organs
Xylene	Category 2	oral, inhalation	-

Aspiration hazard

Product/ingredient name	Result
	ASPIRATION HAZARD - Category 1 ASPIRATION HAZARD - Category 1

Information on likely routes : Not available.

of exposure

Potential acute health effects

Eye contact

-

: Causes serious eye irritation.

Date of issue/Date of revision	: 20/12/2023	Date of previous issue	: No previous validation
SUPREMO KLARLACK 3990-02 -	All variants		

Inhalation	: Can cause central nervous system (CNS) depression. May cause drowsiness o dizziness.
Skin contact	: May cause an allergic skin reaction.
Ingestion	: Can cause central nervous system (CNS) depression.
symptoms related to the phy	ysical, chemical and toxicological characteristics
Eye contact	: Adverse symptoms may include the following: pain or irritation watering redness
Inhalation	: Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness
Skin contact	: Adverse symptoms may include the following: irritation
	redness
Ingestion	redness : No specific data.
-	
	: No specific data.
Delayed and immediate effe	: No specific data.
Delayed and immediate effect Short term exposure Potential immediate	: No specific data. <u>cts as well as chronic effects from short and long-term exposure</u>
Delayed and immediate effect Short term exposure Potential immediate effects	: No specific data. <u>cts as well as chronic effects from short and long-term exposure</u> : Not available.
Delayed and immediate effect Short term exposure Potential immediate effects Potential delayed effects	: No specific data. <u>cts as well as chronic effects from short and long-term exposure</u> : Not available.
Delayed and immediate effect Short term exposure Potential immediate effects Potential delayed effects Long term exposure Potential immediate	 No specific data. cts as well as chronic effects from short and long-term exposure Not available. Not available.
Delayed and immediate effect Short term exposure Potential immediate effects Potential delayed effects Long term exposure Potential immediate effects Potential delayed effects	 No specific data. cts as well as chronic effects from short and long-term exposure Not available. Not available. Not available. Not available.
Delayed and immediate effect Short term exposure Potential immediate effects Potential delayed effects Long term exposure Potential immediate effects Potential delayed effects	 No specific data. cts as well as chronic effects from short and long-term exposure Not available. Not available. Not available. Not available.
Delayed and immediate effect Short term exposure Potential immediate effects Potential delayed effects Long term exposure Potential immediate effects Potential delayed effects Potential delayed effects Potential chronic health eff Not available.	 No specific data. cts as well as chronic effects from short and long-term exposure Not available. Not available. Not available. Not available.
Delayed and immediate effects Potential immediate effects Potential delayed effects Long term exposure Potential immediate effects Potential delayed effects Potential delayed effects Potential chronic health effects	 No specific data. cts as well as chronic effects from short and long-term exposure Not available. Not available. Not available. Not available.
Delayed and immediate effect Short term exposure Potential immediate effects Potential delayed effects Long term exposure Potential immediate effects Potential delayed effects Potential delayed effects Potential chronic health eff Not available. Conclusion/Summary	 No specific data. cts as well as chronic effects from short and long-term exposure Not available. Not available. Not available. Fects Not available. Once sensitized, a severe allergic reaction may occur when subsequently expose
Delayed and immediate effect Short term exposure Potential immediate effects Potential delayed effects Long term exposure Potential immediate effects Potential delayed effects Potential delayed effects Potential chronic health eff Not available. Conclusion/Summary General	 No specific data. cts as well as chronic effects from short and long-term exposure Not available. Not available. Not available. Fects Not available. Once sensitized, a severe allergic reaction may occur when subsequently exposito very low levels.

11.2.1 Endocrine disrupting properties

Not available.

11.2.2 Other information

Not available.

SECTION 12: Ecological information

12.1 Toxicity

SECTION 12: Ecological information

Result	Species	Exposure
Acute LC50 32 mg/l Marine water	Crustaceans - Artemia salina	48 hours
Acute LC50 18000 µg/l Fresh water	Fish - Pimephales promelas	96 hours
Acute EC50 2500000 µg/l Fresh water	Algae - Selenastrum sp.	96 hours
Acute LC50 750000 µg/l Fresh water	Crustaceans - Gammarus pulex	48 hours
Acute LC50 154000 µg/l Fresh water	Daphnia - Daphnia cucullata	48 hours
Acute LC50 212500 µg/l Fresh water	Fish - Heteropneustes fossilis	96 hours
Chronic NOEC 12 mg/l Fresh water	Daphnia - <i>Daphnia magna</i>	21 days
Chronic NOEC 75.6 mg/l Fresh water	Fish - <i>Pimephales promelas</i> - Embrvo	32 days
Acute EC50 >500000 µg/l Marine water	5	96 hours
Acute EC50 5091000 µg/l Fresh water	Daphnia - <i>Daphnia magna</i> - Larvae	48 hours
Acute LC50 3220000 µg/l Fresh water	Fish - Pimephales promelas	96 hours
Acute LC50 130000 µg/l Fresh water	Fish - <i>Pimephales promelas</i> - Adult	96 hours
	Acute LC50 32 mg/l Marine water Acute LC50 18000 µg/l Fresh water Acute EC50 2500000 µg/l Fresh water Acute LC50 750000 µg/l Fresh water Acute LC50 154000 µg/l Fresh water Acute LC50 212500 µg/l Fresh water Chronic NOEC 12 mg/l Fresh water Chronic NOEC 75.6 mg/l Fresh water Acute EC50 >500000 µg/l Marine water Acute EC50 5091000 µg/l Fresh water Acute LC50 3220000 µg/l Fresh water	Acute LC50 32 mg/l Marine water Acute LC50 18000 µg/l Fresh water Acute EC50 2500000 µg/l Fresh water Acute LC50 750000 µg/l Fresh water Acute LC50 154000 µg/l Fresh water Acute LC50 212500 µg/l Fresh water Chronic NOEC 12 mg/l Fresh water Chronic NOEC 75.6 mg/l Fresh water Acute EC50 5091000 µg/l Fresh water Acute EC50 5091000 µg/l Fresh water Acute LC50 3220000 µg/l Fresh water Acute LC50 3220000 µg/l Fresh water Acute LC50 130000 µg/l Fresh water Acute LC50 130000 µg/l Fresh waterCrustaceans - Artemia salina Fish - Pimephales promelas Algae - Selenastrum sp. Crustaceans - Gammarus pulex Daphnia - Daphnia cucullata Fish - Heteropneustes fossilis Daphnia - Daphnia magna Fish - Pimephales promelas - EmbryoAcute EC50 >500000 µg/l Fresh water Acute LC50 3220000 µg/l Fresh water Acute LC50 130000 µg/l Fresh waterAlgae - Skeletonema costatum Daphnia - Daphnia magna - LarvaeAcute LC50 3220000 µg/l Fresh water Acute LC50 130000 µg/l Fresh waterFish - Pimephales promelas Fish - Pimephales promelas -

12.2 Persistence and degradability

Conclusion/Summary	: This product has not been tested for biodegradation.
	· The product has not been tooled for broadgradation.

12.3 Bioaccumulative potential

Product/ingredient name	LogPow	BCF	Potential
n-Butyl acetate	2.3	-	Low
Ethyl acetate	0.68	30	Low
Butanone	0.3	-	Low
Naphtha (petroleum), hydrotreated light	2.2 to 5.2	10 to 2500	High
2-Methoxy-1-methylethyl acetate	1.2	-	Low
Xylene Methyl methacrylate	3.12 1.38	8.1 to 25.9 -	Low Low

12.4 Mobility in soil	
Soil/water partition coefficient (Koc)	: Not available.
Mobility	: Not available.

12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

12.6 Endocrine disrupting properties

Not available.

12.7 Other adverse effects

No known significant effects or critical hazards.

SECTION 13: Disposal considerations

13.1 Waste treatment methods
Product

SECTION 13: Disposal considerations

Methods of disposal	: The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.
Hazardous waste	: The classification of the product may meet the criteria for a hazardous waste.
European waste catalogue (EWC)	: 08.01.11
Packaging	
Methods of disposal	: The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.
Special precautions	: This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Vapour from product residues may create a highly flammable or explosive atmosphere inside the container. Do not cut, weld or grind used containers unless they have been cleaned thoroughly internally. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

SECTION 14: Transport information

	ADR/RID	ADN	IMDG	ΙΑΤΑ
14.1 UN number or ID number	UN1993	UN1993	UN1993	UN1993
14.2 UN proper shipping name	FLAMMABLE LIQUID, N.O.S. (n-butyl acetate, ethyl acetate)	FLAMMABLE LIQUID, N.O.S. (n-butyl acetate, ethyl acetate)	FLAMMABLE LIQUID, N.O.S. (ethyl acetate, 2-methoxy- 1-methylethyl acetate)	FLAMMABLE LIQUID, N.O.S. (ethyl acetate, 2-methoxy- 1-methylethyl acetate)
14.3 Transport hazard class(es)	3	3	3	3
14.4 Packing group	11	11	II	II
14.5 Environmental hazards	No.	Yes.	No.	No.
Additional information ADR/RID : Special provisions 640 (C) Tunnel code (D/E) ADN : The product is only regulated as an environmentally hazardous substance when transported in tank vessels. Special provisions 640 (C)				
14.6 Special precautions for : Transport within user's premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.				
14.7 Maritime transport in : Not relevant/applicable due to nature of the product. bulk according to IMO instruments				

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture <u>EU Regulation (EC) No. 1907/2006 (REACH)</u>

Annex XIV - List of substances subject to authorisation

ż

Annex XIV

None of the components are listed.

Substances of very high concern

None of the components are listed.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

Product/ingredient name	%	Designation [Usage]
SUPREMO KLARLACK 3990-02	≥90	3

Labelling

Other EU regulations

<u>Julei Eu regulations</u>		
Industrial emissions (integrated pollution prevention and control) - Air	:	Not listed
Industrial emissions (integrated pollution prevention and control) - Water	:	Not listed
Explosive precursors	1	Not applicable.
Ozone depleting substanc	es	<u>(1005/2009/EU)</u>
Not listed.		

Prior Informed Consent (PIC) (649/2012/EU)

Not listed.

Persistent Organic Pollutants

Not listed.

Seveso Directive

This product is controlled under the Seveso Directive.

Danger criteria

Category	
P5c	

International regulations

<u>Chemical Weapon Convention List Schedules I, II & III Chemicals</u> Not listed.

Montreal Protocol

Not listed.

Stockholm Convention on Persistent Organic Pollutants

Not listed.

Rotterdam Convention on Prior Informed Consent (PIC) Not listed.

UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

SECTION 15: Regulatory information

15.2 Chemical safety assessment

: This product contains substances for which Chemical Safety Assessments are still required.

SECTION 16: Other information

Indicates information that has changed from previously issued version.

Abbreviations and	: ATE = Acute Toxicity Estimate
acronyms	CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No.
-	1272/2008]
	DMEL = Derived Minimal Effect Level
	DNEL = Derived No Effect Level
	EUH statement = CLP-specific Hazard statement
	N/A = Not available
	PBT = Persistent, Bioaccumulative and Toxic
	PNEC = Predicted No Effect Concentration
	RRN = REACH Registration Number
	SGG = Segregation Group
	vPvB = Very Persistent and Very Bioaccumulative

Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Classification	Justification
Flam. Liq. 2, H225	On basis of test data
Eye Irrit. 2, H319	Calculation method
Skin Sens. 1, H317	Calculation method
STOT SE 3, H336	Calculation method
Aquatic Chronic 3, H412	Calculation method

Full text of abbreviated H statements

H225	Highly flammable liquid and vapour.
H226	Flammable liquid and vapour.
H304	May be fatal if swallowed and enters airways.
H312	Harmful in contact with skin.
H315	Causes skin irritation.
H317	May cause an allergic skin reaction.
H319	Causes serious eye irritation.
H332	Harmful if inhaled.
H335	May cause respiratory irritation.
H336	May cause drowsiness or dizziness.
H373	May cause damage to organs through prolonged or repeated exposure.
H411	Toxic to aquatic life with long lasting effects.
H412	Harmful to aquatic life with long lasting effects.
EUH066	Repeated exposure may cause skin dryness or cracking.

Full text of classifications [CLP/GHS]

Acute Tox. 4	ACUTE TOXICITY - Category 4
Aquatic Chronic 2	LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 2
Aquatic Chronic 3	LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 3
Asp. Tox. 1	ASPIRATION HAZARD - Category 1
Eye Irrit. 2	SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2
Flam. Liq. 2	FLAMMABLE LIQUIDS - Category 2
Flam. Liq. 3	FLAMMABLE LIQUIDS - Category 3
Skin Irrit. 2	SKIN CORROSION/IRRITATION - Category 2
Skin Sens. 1	SKIN SENSITISATION - Category 1
Skin Sens. 1A	SKIN SENSITISATION - Category 1A
STOT RE 2	SPECIFIC TARGET ORGAN TOXICITY - REPEATED EXPOSURE - Category 2
STOT SE 3	SPECIFIC TARGET ORGAN TOXICITY - SINGLE EXPOSURE - Category 3
Date of issue/ Date of	: 20/12/2023
revision	
Date of previous issue	No previous validation

Date of previous issue	: No previous validation
Version	: 1

SUPREMO KLARLACK 3990-02

All variants

Notice to reader

SECTION 16: Other information

The information in this SDS is based on the present state of our knowledge and on current laws. The product is not to be used for purposes other than those specified under section 1 without first obtaining written handling instructions. It is always the responsibility of the user to take all necessary steps to fulfil the demands set out in the local rules and legislation. The information in this SDS is meant to be a description of the safety requirements for our product. It is not to be considered a guarantee of the product's properties.